# A Study of Golimumab in Participants With Active Psoriatic Arthritis

> **NCT02181673** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 480 (actual)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **DRUG:** Placebo
- **DRUG:** Golimumab

## Key facts

- **NCT ID:** NCT02181673
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-08
- **Primary completion:** 2016-05-05
- **Final completion:** 2017-03-22
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2017-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181673, "A Study of Golimumab in Participants With Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT02181673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*